Brief: Frequency Therapeutics Completes Enrollment Of Phase 2B Study Of FX-322 For The Treatment Of Sensorineural Hearing Loss

Korro Bio

12/10/2022 12:36

Oct 12 (Reuters) - Frequency Therapeutics Inc  FREQ.O :
    * FREQUENCY THERAPEUTICS COMPLETES ENROLLMENT OF PHASE 2B
STUDY OF
FX-322 FOR THE TREATMENT OF SENSORINEURAL HEARING LOSS
    * FREQUENCY THERAPEUTICS INC - READOUT EXPECTED IN Q1 2023
    * FREQUENCY THERAPEUTICS INC - COMPANY ALIGNED WITH FDA ON
SPEECH
PERCEPTION PRIMARY ENDPOINT

Source text for Eikon:  ID:nBw8xFC04a 
Further company coverage:  FREQ.O 
 ((Reuters.Briefs@thomsonreuters.com;))